Fatty Liver Disease
34
11
12
9
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
2.9%
1 terminated out of 34 trials
90.0%
+3.5% vs benchmark
3%
1 trials in Phase 3/4
22%
2 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (34)
Impact of Ganoderma Lucidum on NRF2 Levels and Antioxidant Status in Metabolic Asscociated Fatty Liver Disease (GL-MAFLD-NRF2 Study)
Assessment of Fatty Liver With Thermo-acoustic Device
A Research Study of a Potential New Medicine (NNC4005-0001) for Liver Disease in Adult Participants With Increased Body Weight and Liver Fat
Digoxin In NASH (CODIN)
Liver Disease and Other Systemic Diseases
Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly
Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load
A Single and Multiple Ascending Dose Study of Subcutaneously Administered JNJ-75220795
LivQ-box® Parameters in the Diagnosis of Liver Inflammation
The Evaluation of Orange Peel Fermentation on Body Fat Lowering Efficacy in Adults
The Role of Sugars in Fat Accumulation in the Liver
NAC- NAFLD and Cushing
Assessment of FibbroScan in Diagnosing MASLD Among the Chinese Population With Obesity
Metabolic Associated Fatty Liver Disease in Patients With Chronic Glomerular Disease
Synbiotics Impact on Insulin and TNF-α in MAFLD: a Gut Microbiota Profile Analysis
Effect of Intermittent Calorie Restriction on MASLD Patients With Abnormal Glucose Metabolism
Metabolic Syndrome and Fatty Liver Disease Among Egyptian Patients with Chronic HBV
Impact of Fatty Liver on Hepatitis B Therapy
Effect of Sodium Glucose Cotransporter Inhibitors Fatty Liver Disease Patients Fatigue Assessment
A Clinical Study of Ultrasound-derived Fat Fraction to Assess Metabolic Dysfunction-Associated Steatotic Liver Disease